Kornimate/medical-research-clean huggingface dataset:
platelet rich fibrin+1% alendronate in treatment of mandibular degree ii furcation defects

Conditions: Furcation Defects

Summary: the present study was designed to evaluate the combined efficacy of prf and 1% aln in the treatment of mandibular degree ii furcation defects when compared with prf and open flap debridement (ofd) alone.

background: various regenerative materials have been introduced and tested in the treatment of furcation defects. platelet-rich fibrin (prf) is a reservoir of growth factors and cytokines which are the key factors for regeneration of bone and maturation of the soft tissue. alendronate (aln), a potent member of bisphosphonate group is known to promote tissue regeneration by inhibiting osteoclastic bone resorption and promoting osteoblastogenesis. the present study was designed to evaluate the combined efficacy of prf and 1% aln in the treatment of mandibular degree ii furcation defects when compared with prf and open flap debridement (ofd) alone. methods: seventy two mandibular furcation defects were treated with either ofd alone (group 1), ofd with prf (group 2), and ofd with prf+1% aln (group 3). clinical parameters; site specific plaque index (pi), modified sulcus bleeding index (msbi), probing depth (pd), relative vertical attachment level (rval) and relative horizontal attachment level (rhal), intrabony defect depth (ibd) were recorded at baseline before surgery and 9 months post-operatively. percentage radiographic defect fill was evaluated at baseline and 9 months.

Eligibility criteria:
inclusion criteria: * presence of buccal class ii furcation defects in endodontically vital, asymptomatic mandibular first and second molars with a radiolucency in the furcation area on an intraoral periapical radiograph with probing depth (pd) ≥ 5mm and horizontal ≥ pd 3mm after phase i therapy i.e, scaling and root planing (srp); * no history of antibiotic or periodontal therapy in the preceding 6 months. exclusion criteria: * systemic conditions known to affect the periodontal status; * medications known to affect the outcomes of periodontal therapy; * hematological disorders and insufficient platelet count (\<200,000/mm3); * pregnancy/lactation; * smoking and tobacco use in any form * immunocompromised individuals; * those having unacceptable oral hygiene (plaque index \[pi\] \>1.5). * teeth with furcation involvement, non-vital teeth, and carious teeth indicated for restorations and mobility of at least grade ii * aggressive periodontitis
co2-patterns during hyperoxia and physical exercise in copd

Conditions: COPD

Summary: the aim of the study is to investigate a possible correlation between the change in pco2 during a hyperoxia-test and the change in pco2 during walking in people with copd

rationale: carbon dioxide partial pressure (pco2) varies significantly in patients with advanced chronic obstructive pulmonary disease (copd). data from the swedish ltot registry showed that pco2 is an independent predictor for mortality and that there is a u-shaped relationship. patients with advanced copd who are still normocapnic at rest may still develop a clinically relevant, exercise-induced carbon dioxide (co2) retention during exercise/ activity. it is also known that altered breathing patterns at night in copd patients can lead to nocturnal hypercapnia, especially during rem sleep. the course of pco2 cannot be reliably predicted by lung function parameters or resting blood gas analysis. since exercise tests with blood gas control or nightly pco2 monitoring are rarely performed in clinical routine, exercise induced co2 retention often remains undetected. in the literature, there is little information on pco2 behaviour under everyday conditions (with or without ltot) such as rest, physical exertion and nightly sleep. therefore, predictors that could describe the pco2 patterns are missing. however, one former study by o'donnel from 2002 showed that the change in co2 under hyperoxia conditions could provide predictive information for the change in co2 with exercise. objective: primary aim of this study is to investigate whether the change of pco2 during a hyperoxia-test (10l/min o2 at rest) correlates with the change of pco2 during walking exercise with either a: l/min o2 as prescribed; b: medical air; c: 10l/min o2. design: this study is a randomized, controlled cross-over trial. following an initial maximal incremental shuttle walk test (iswt), the participant will perform 3 endurance shuttle walk tests (eswt) at 85% of the maximum iswt pace on three consecutive days (24h break between eswts). in a randomized order, participants will perform one eswts with o2-flow as prescribed (e.g. study day 1), one with medical air (same flow rate as prescribed oxygen) (e.g. study day 2) and one with 10l/min o2 (e.g. study day 3). an additional hyperoxia test (10l/min o2 for ten minutes; at resting condition) will be perfomed on each day prior to performing an eswt.

Eligibility criteria:
inclusion criteria: * copd iii/ iv * 35mmhg \< pco2 \<= 55mmhg (under resting conditions, breathing room air) * hypoxemia (pao2\<60mmhg) under room air conditions (rest or during exercise) or spo2 \<88% during exercise * established oxygen therapy or given indication for oxygen therapy * written informed consent exclusion criteria: * acute exacerbation of copd * exercise limiting cardiac or orthopedic comorbidites * pao2 \<50mmhg at rest, breathing room air

Keywords: co2 oxygen walking exercise
effect of exercise and omega-3 on metabolic health in elderly

Conditions: Metabolism Disorder; Adiposity; Inflammatory Response

Summary: the aim of this project is to investigate in elderly women, the effect of combined aerobic and resistive training and concomitant supplementation with omega-3 fatty acids on adipogenesis, metabolic functions and pro-inflammatory status of adipose tissue and on systemic metabolic profile.

aging is associated with development of disturbances of lipid and carbohydrate metabolism and with systemic pro-inflammatory state similarly to the alterations observed in obese individuals. metabolic and immune dysfunction of adipose tissue has been suggested as an important contributing trigger to this condition. exodya project is a clinical study in elderly individuals that aims to establish benefits of lifestyle intervention and nutritional supplementation -either alone or in combination- for the amelioration of systemic and adipose tissue metabolic and immune disturbances. effects of 4 months´ intervention with combined aerobic plus resistive exercise training and supplementation with omega-3 polyunsaturated fatty acids on systemic metabolic profile and molecular characteristics of adipose tissue will be investigated in elderly women. thus, a proof-of-concept will be provided for novel recommendations and guidelines for lifestyle interventions in elderly population

Eligibility criteria:
inclusion criteria: * elderly women: age 60-80 * non-trained (without regular physical activity) * bmi in the range of 25-30 kg/m2 exclusion criteria: * diagnosed cancer, diabetes, liver and renal diseases, untreated hyper- or hypo-thyroidism, long term use of anti-inflammatory medication (anti-rheumatics and analgesics affecting cyclooxygenases (100 mg of anopyrin daily is acceptable), steroids and/or omega-3 dietary supplements

Keywords: elderly exercise training adipose tissue omega-3 polyunsaturated fatty acids inflammation diferentiation of preadipocytes
study on the effect of 3t pu'er tea in regulating glucose and lipid metabolism

Conditions: Overweight; Obesity

Summary: to study the effect of pu'er tea in overweight / obese patients with blood glucose or abnormal lipid metabolism. compared with the effect of two pu'er tea with different tea fuscin content in improving glucose and lipid metabolism, to investigate the mechanisms of bile acid metabolism and intestinal flora regulation. in a prospective randomized controlled clinical study, 90 patients were divided into study group (3t pu'er tea group, 45 patients) and control group ( traditional pu'er tea group,45 patients). before and after the treatment(0day, 12 weeks, 52 weeks) patients' markers of glucose and lipid metabolism were examined and compared.


Eligibility criteria:
inclusion criteria: the a、b should be simultaneously met, or combined with the c、d、e. 1. 18-65 years, priority for patients over 30 years; 2. overweight / obese patients: bmi ≥24 kg/m2. 3. or combined with nonalcoholic fatty liver disease: determined by the hospital mri nuclear magnetic quantification; 4. or combined with dyslipidemia: blood total cholesterol tc≥6.4mmol/l or blood total triglyceride tg≥2.0mmol/l or blood low-density lipoprotein ldl-c≥3.1mmol/l; 5. or with abnormal blood glucose: * impaired fasting glucose, ifg: fasting blood glucose was 6.1\~\<7.0mmol/l,and 2 hours after 75g oral blood glucose tolerance test(ogtt) \<7.8mmol / l. * impaired glucose tolerance, igt: the fasting blood glucose was \<6.1mmol/l and 2 hours after 75gogtt was 7.8\~ \<11.1 mmol / l; * ifg with igt: patients with both ifg and igt; * patients with type 2 diabetes: random blood glucose 11.1mmol/l or fasting glucose of 7.0 mmol/l or 2 hours after ogtt. exclusion criteria: 1. type 2 diabetes and insulin injections or oral hypoglycemic drugs and other special types of diabetes. 2. for women during pregnancy or lactation or with allergies; 3. patients treated with any hypoglycemic drugs and insulin injections; regular or planned patients taking drugs that may affect glucose and lipid metabolism (as judged by clinicians, such as diet pills, lipid-lowering drugs) and liver protection drugs (as judged by clinicians); 4. patients with severe cardiovascular diseases, cerebrovascular diseases, liver, kidney, and hematopoietic diseases; 5. combined with other infectious diseases, such as hepatitis a, hepatitis b, hepatitis c, and acquired immunodeficiency syndrome; 6. take probiotics, prebiotics, antioxidants and fish oil nutrient supplements within 3 months; 7. current smokers and regular drinking (excluding social drinkers only); 8. yogurt intake within 1 week before the first visit and antibiotics within 3 months; 9. drink strong tea regularly; 10. participate in other clinical trials within 3 months; 11. unable not cooperate with the investigator for other reasons. 12. unfit for the researcherr.

Keywords: pu' er tea glucose and lipid metabolism intestinalflora
a multicountry, multicentre, non-interventional, retrospective study to determine real-world treatment patterns and associated outcomes after first line osimertinib in patients with advanced and metastatic nsclc egfrm in the gcc region

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: a multicountry, multicenter, non-interventional, retrospective study to determine real-world treatment patterns and associated outcomes after first line osimertinib in patients with advanced and metastatic nsclc harboring egfr-activating mutations in the gcc region

osimertinib has demonstrated superior pfs compared to firstgeneration egfr-tkis (erlotinib and gefitinib) in the first line setting in clinical trials. there remains a need to consider clinical outcomes in the real-world setting and determine the characteristics of long-term survivors in the real world. it will also be important to determine the subsequent treatment pathways of patients who progress on treatment with osimertinib

Eligibility criteria:
inclusion criteria: for inclusion in the study, all the following inclusion criteria must be fulfilled: 1. patients with stage iiib-iv nsclc using either ajcc 7th or 8th edition with egfr mutation. 2. age 18 or older at index date (specific age may vary according to country-specific guidelines) 3. treated in the first line with osimertinib from (april 1st, 2018, until december 31st, 2021). 4. medical records available at the participating site reflect at least 9 months of follow-up from the index date (unless the patient died within the first 9 months of diagnosis). note: specific databases may have additional inclusion criteria which will be detailed in country-specific protocol adaptations and statistical analysis plans (saps). exclusion criteria: subjects are not eligible for this study if they fulfil any of the following exclusion criteria: 1. failure to meet one or more of the inclusion criteria. 2. patients who received curative crt within 3 months and/or any first-line systemic anti-cancer therapies (sact) for advanced/metastatic nsclc for \>28 days prior to osimertinib start. 3. patients who have prior exposure of i/o therapy.
bilirubin neurotoxicity (bn) and neurodevelopmental impairment (ndi) in extremely preterm (ep) infants: avoidable by reducing the usual intravenous lipid (ul) administration

Conditions: Bilirubin Encephalopathy

Summary: the purpose of this study is to evaluate the effect of usual versus reduced lipid intake on unbound bilirubin levels, brainstem auditory evoked responses, and neurodevelopmental outcome at 2 years in extremely preterm infants.


Eligibility criteria:
inclusion criteria: * no major congenital anomaly or overt nonbacterial infection * mother has consented to inclusion of the infant for the neonatal research network (nrn) cycled phototherapy trial exclusion criteria: * has received intralipid

Keywords: preterm bilirubin lipid emulsions unbound bilirubin unbound free fatty acids
korean post-marketing surveillance for onglyza®

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of onglyza® so that the regulatory authority can manage the marketing approval properly.


Eligibility criteria:
inclusion criteria: * female and male patients who are at least 18 years of age * patients with diagnosis of t2dm initiating onglyza® treatment within the approved indications in korea exclusion criteria: * indication which is not approved for onglyza® in korea * patients with contraindication for the use of onglyza® (as clarified in korean label)
the effect of vitamin b3 on substrate metabolism, insulin sensitivity, and body composition in obese men

Conditions: Obese

Summary: in animals, treatment with vitamin b3 improved insulin sensitivity and substrate metabolism. it is currently not know if vitamin b3 has the same positive effects in humans. in the current study the effect of a 3 month treatment with vitamin b3 on insulin sensitivity and substrate metabolism in obese men will be investigated.


Eligibility criteria:
inclusion criteria: * written signed consent * male * bmi\>30 kg/(m2) * age: 40-70 * no medication * non-smoker exclusion criteria: * endocrine disease * other severe disease * high daily activity level (\>30 min / day)
to evaluate the clinical study of gs1191-0445 injection in the treatment of hemophilia a

Conditions: Hemophilia A

Summary: this study is a single-arm, open-label, multicenter study evaluating the efficacy and safety of gs1191-0445 injection as a single dose in chinese subjects with hemophilia a. gs1191-0445 is an aav8-based gene therapy vector designed to express b-domain deleted human factor viii (fviii) under the regulation of a human liver-specific promoter. following a single intravenous administration, aav8 targets hepatocytes and facilitates the specific expression and secretion of fviii into the bloodstream.


Eligibility criteria:
inclusion criteria: 1. understand the purpose and risks of the study and provide informed consent in accordance with national and local privacy laws: 2. subject must be male, aged \>18 years old at the time of signing informed consent, and ≤65 years old: 3. participants with confirmed hemophilia a in their pre-admission history and based on clinical laboratory examination ; 4. subjects had used fvii products for at least 150 exposure days (ed) before enrollment; 5. subject has no prior history of fviii inhibitors; 6. subjects agree to use a reliable barrier contraceptive method from the date of signing the informed consent 7. subject is willing and able to follow planned visits, treatment plans, and other study procedures. exclusion criteria: 1. the subject has any hemorrhagic disorder not related to hemophilia a, 2. abnormal liver function test results of subjects during screening. 3. abnormal laboratory examination of subjects during screening 4. the subject has acute or chronic hepatitis b virus (hbv) infection or chronic hepatitis c virus (hcv) infection; or are receiving antiviral treatment for hepatitis b and c; 5. active systemic immune disease.
comparison between continuous versus interval exercise training in asthmatic patients

Conditions: Asthma

Summary: the treatment of asthma is based in clinical control. however, previous studies have been shown that patients that participate of the programs of regular or aerobic continuous exercise training (ct) presented improvements in the physical conditioning, and quality life, as well as decreased the levels of anxiety and depression, reduced the oxide nitric exhaled and leukocyte migration at the airways and reduced the airway hyperresponsiveness. the regular exercise also is important part in the rehabilitation of other lung disease as well as chronic obstructive pulmonary disease (copd). additionally, others studies have been shown the effects of high intensity interval training (it) in the pulmonary rehabilitation of copd patients, that after performed it presented reduction of dyspnea, and increase the physical capacity. in this sense, the impact of it in the asthmatic patients at the present moment is poorly studied, and necessity of the more investigation to prove the efficiency of this training model for asthma patients. .

the present study will compare the impact of it and ct in patients with moderate or severe asthma, and investigate what is the most efficient and increases the physical capacity, and quality of life and reduces the inflammatory mediators. sixty asthmatic adults will be randomly assigned into two groups: ct (continuous training) or it (interval training). ct will have treatment 2x week, 40 min./session, 60-75% of maximum heart rate intensity and it also 2x week, 40 min./session, 80-140% of the maximum load intensity, both performed in ergometer cycle by 24 weeks.

Eligibility criteria:
inclusion criteria: * asthma moderate and severe * asthma will diagnosed (global initiative for asthma - gina) * body mass index (bmi) \< 35kg/m2 * medical treatment for at least 6 months * clinically stable (i.e., no exacerbation or medication changes for at least 30 days) exclusion criteria: * cardiovascular, musculoskeletal or other different chronic lung diseases * active cancer * pregnant * smokers

Keywords: asthma continuous exercise training interval exercise training clinical control inflammation
predicting medication response for autoimmune disease

Conditions: Ulcerative Colitis; Crohn's Disease; Psoriasis; Rheumatoid Arthritis

Summary: coral is conducting a large study comparing and predicting the relative effectiveness of different medications for autoimmune patients. patients with inflammatory bowel disease (ibd) who have been diagnosed with either ulcerative colitis or crohn's disease and are undergoing treatment are eligible to participate. patients with rheumatoid arthritis (ra) and psoriasis (ps) will also be enrolled. a novel clinical test will be performed to predict the responsiveness of a particular patient to different immune modulating therapies used in these conditions.


Eligibility criteria:
inclusion criteria: * ulcerative colitis, crohn's disease, rheumatoid arthritis, psoriasis diagnosis * on or about to begin a treatment for condition above
fnirs in the evaluation of cognitive-motor interference in post-stroke patients

Conditions: D020521

Summary: this study evaluates cognitive-motor interference in stroke patients who is responsible an alteration of spatio-temporal gait parameters. it's proved in the literature but the underlying pathophysiological mechanisms remain poorly understood. fnirs is a functional imaging technique that evaluates this interference under optimal conditions. the purpose of this study is to evaluate the hemodynamic activity of the cpf in walking post-stroke patients under different dt conditions.

walking is a motor task that involves cognitive functions. the parameters of walking and brain activity are modified in situations requiring significant attentional and cognitive demand. fnirs is an interesting functional neuroimaging technique for studying cortical activity when performing a dual task (dt). to our knowledge, no studies have examined cerebral oxygenation levels in post-stroke patients based on different cognitive loads during walking. understanding cognitive contributions in a dual-task walking situation is necessary to providing targeted interventions and preventing falls. patients included in the study will be evaluated in single cognitive task, with two levels of difficulty, single walking motor task, and dual task with two levels of cognitive difficulty. the fnirs will record the hemodynamic activity of the prefrontal cortex for the cognitive slope and the gaitrite will record the walking parameters.

Eligibility criteria:
inclusion criteria: * patient between 55 and 75 years old * first stroke * ischemic sylvian or hemorrhagic lobar deep respecting the frontal lobe, subacute phase (j15-j90), * patient walking 10 meters. exclusion criteria: * heminegligencia, * a history of neurological pathologies, orthopedic pathologies, aphasia, cognitive disorders preceding stroke (dementia, head trauma), acute cardiovascular or respiratory pathologies.

Keywords: stroke, dual-task, gait parameters, fnirs
urine chloride/creatinine ratio for estimation of urine sodium

Conditions: Hypertension

Summary: we plan to assess the accuracy of a new means of estimating urine sodium excretion. we will compare the chloride to creatinine ratio obtained by titrator sticks with urine sodium measured by a standard laboratory. if found to approximate sodium excretion, the titrator sticks could provide a convenient means for doctors and patients to monitor their salt intake.

level of salt intake has an important impact in patients with high blood pressure or congestive heart failure. despite this there is no convenient way for doctors or patients to assess their salt intake other than diet recall, which is unreliable, or measurement of sodium excretion in a 24 hour collection of urine, which is very inconvenient. as a result, salt intake is not monitored in most patients. 2 innovations might enable a more convenient assessment of salt intake. a titrator stick that measures chloride ion concentration (chloride and sodium concentrations correlate strongly with each other), and a titrator stick that measures urine creatinine. the latter enables estimation of 24 hour excretion from a single sample of urine. in assessing sodium intake, a measurement that provides an approximation of urine sodium intake would be of considerable clinical value in this study, we shall compare the estimation of urine sodium excretion measured by a laboratory with estimation of sodium excretion from measurement of chloride/creatinine ration in a random urine sample. we will compare the estimate obtained by titrator stick with the sodium concentration from the same urine sample, and from measurements obtained from a 24 hour urine collection. in the next phase we will also compare the average estimate from titrator stick obtained on 3 different days with the measurement obtained from 3 24 hour urine collections. we will assess the accuracy with which the titrator stick estimate approximates the measured urine sodium. as of march 2007, we have recruited 50 subjects, and continue to study the predictive value of spot urine chloride/creatinine ratio, as described.

Eligibility criteria:
inclusion criteria: over 21 years of age. exclusion criteria: no exclusion criteria.

Keywords: sodium intake sodium excretion chloride excretion creatinine hypertension